New pill targets Cancer's DNA repair in advanced tumors
NCT ID NCT05898399
Summary
This early-stage study is testing a new oral drug called ART6043, both by itself and combined with an existing cancer drug (olaparib), in people with advanced or spreading solid tumors. The main goals are to find safe doses and see early signs of whether the treatment helps control cancer growth. It will enroll about 220 participants with specific types of cancer, including certain breast cancers with genetic changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jefferson University Hospitals - Kimmel Cancer Center
Philadelphia, Pennsylvania, 17107, United States
-
Mary Crowley Cancer Center - Clinic
Dallas, Texas, 75251, United States
-
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York, 10065-6800, United States
-
SCRI oncology partners
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START) - Midwest
Grand Rapids, Michigan, 49546, United States
-
Stephenson Cancer Center - Oncology
Oklahoma City, Oklahoma, 73104, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.